A detailed history of Luts & Greenleigh Group, Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Luts & Greenleigh Group, Inc holds 3,942 shares of BMY stock, worth $217,913. This represents 0.2% of its overall portfolio holdings.

Number of Shares
3,942
Previous 7,320 46.15%
Holding current value
$217,913
Previous $304 Million 32.9%
% of portfolio
0.2%
Previous 0.32%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 15, 2024

SELL
$39.66 - $51.75 $133,971 - $174,811
-3,378 Reduced 46.15%
3,942 $204 Million
Q2 2024

Aug 09, 2024

BUY
$40.25 - $52.99 $294,630 - $387,886
7,320 New
7,320 $304 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $118B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Luts & Greenleigh Group, Inc Portfolio

Follow Luts & Greenleigh Group, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Luts & Greenleigh Group, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Luts & Greenleigh Group, Inc with notifications on news.